Biotech & AI drug discoverySTAT — Biotech

STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

A multiple sclerosis (MS) treatment from Novartis cut the rates of relapses by one-third compared to a standard treatment in pivotal trials.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-23T16:47:31+00:00

Published here2026-10-23T17:11:58+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/23/novartis-remibrutinib-multiple-sclerosis-trial-results/

Original headline

STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.